FDA Testosterone Label Change: What It Means for TRT

Two things happened to testosterone therapy in the summer of 2026, and they point in opposite directions. The FDA testosterone label change made prescribing for age-related low testosterone considerably easier to defend on paper. Weeks later, the Endocrine Society and a study presented at ENDO 2026 made it much harder to defend how most of that prescribing is actually being done.

Both are correct. Taken together they describe the situation men on TRT are now in fairly precisely: the therapy has better safety evidence behind it than it did five years ago, and the diagnostic work that should precede it is being skipped most of the time.

What the FDA testosterone label change actually did

In June 2026, HHS announced through FDA that it was requesting updates to the prescribing information across testosterone replacement products, following a review of new clinical data (1). The substantive changes:

The age-related hypogonadism limitation comes off. Labels had carried a limitation of use stating that the safety and effectiveness of testosterone therapy in men with age-related hypogonadism had not been established. FDA requested its removal (1).

This is the big one. That sentence was the single most cited reason for treating age-related low testosterone as off-label, borderline, or something a cautious physician avoided. It shaped a generation of clinical reluctance — and, by pushing men toward less careful sources, arguably did as much harm as good.

Prostate cancer information is updated and the contraindication narrowed. The historical position — testosterone as categorically contraindicated in prostate cancer — has been narrowing for years as the evidence for the old androgen-drives-cancer model weakened. The revised labeling reflects a narrower contraindication centred on metastatic disease.

The BPH warning is revised. Updated to reflect evidence that testosterone therapy does not generally worsen lower urinary tract symptoms in most appropriately monitored men.

What did not change: the blood pressure warning. In 2025, FDA issued class-wide labeling changes requiring product-specific blood pressure information after postmarket ambulatory blood pressure monitoring studies found that testosterone products increase blood pressure, including adding warnings to products that had not previously carried one (2). That stayed. It is the most clinically actionable line on the label and the one most likely to be glossed over in a piece celebrating the other changes.

Four things the label change does not mean

The changes are already being oversold, so to be explicit about the boundaries:

It is not an expansion of who should be treated. Removing a statement that something was unstudied is not the same as recommending it. The indication is still symptomatic hypogonadism confirmed by testing, not low-normal testosterone in a man who would like to feel better.

It is not a finding that testosterone is cardioprotective. TRAVERSE tested whether harm was present and did not find it at the primary endpoint. Some marketing is already running this backwards.

It does not remove the monitoring burden. Haematocrit, PSA where indicated and blood pressure are all still on the label, and the blood pressure requirement is newer than the reassurance is.

It does not make testosterone appropriate for fertility-seeking men. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and with it sperm production. No labeling change alters that physiology.

The evidence behind it: TRAVERSE

The label change rests substantially on TRAVERSE, the cardiovascular safety trial FDA required after years of conflicting observational signals (3).

The design is what makes it useful:

• Over 5,200 men, aged 45 to 80
• All with symptomatic hypogonadism
• All with existing cardiovascular disease or elevated cardiovascular risk — deliberately the population where harm, if present, would show
• Randomized to testosterone gel or placebo
• Primary endpoint: major adverse cardiac events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)

The result was non-inferiority: testosterone did not increase major adverse cardiac events compared with placebo (3).

Three caveats belong with that headline, and you will not always be given them.

First, non-inferiority is not benefit. TRAVERSE showed the therapy did not raise cardiac risk in this population. It was not designed to show it lowers it.

Second, the trial studied gel, not injections or pellets. Route matters for pharmacokinetics, for peak levels, and for haematocrit. Extrapolating a gel result to every formulation is an assumption, not a finding.

Third, secondary signals were noted — including atrial fibrillation, pulmonary embolism and acute kidney injury — and postmarket work drove the blood pressure warning that remains on the label. The label got friendlier overall; it did not become blank.

And then the other half of the summer

On 16 July 2026, the Endocrine Society published a statement reinforcing the importance of accurate diagnosis and appropriate clinical assessment before testosterone replacement is started in men with hypogonadism (4).

The timing was not an accident. It landed alongside a study presented at ENDO 2026 that is, frankly, the most useful thing published on TRT this year (5).

Researchers reviewed the charts of 200 men with a hypogonadism diagnosis who received an initial testosterone prescription at a large academic health system between 2020 and 2025. They asked a simple question: how many of them had the diagnostic workup the guidelines call for?

Twelve percent.

The criteria were not exotic. Guideline-concordant meant:

• Two low morning testosterone measurements — total testosterone below 300 ng/dL, free testosterone below 70 pg/mL, or low bioavailable testosterone — drawn between roughly 5 and 10 a.m.
• LH and/or FSH measured, to distinguish testicular failure from a pituitary or hypothalamic cause
• No contraindications to therapy

Supporting numbers from the same review: 62% had a PSA drawn before the prescription; 77% had a complete blood count. Fifty-five percent had obstructive sleep apnoea — a condition that both mimics low testosterone symptomatically and is worsened by treating it without addressing the apnoea. Four percent had prostate cancer.

Prescriptions came from primary care 45% of the time, urology 35.5%, endocrinology 18% (5).

The authors’ conclusion was measured: improving guideline-concordant prescribing “can help prevent avoidable risks in people who may not have a true clinical need for it” (5).

Why the diagnostic bar is not bureaucracy

Each element of that workup exists because skipping it causes a specific, predictable problem.

Two morning draws, not one. Testosterone has a marked diurnal rhythm — highest in the early morning, falling through the day. It also swings substantially day to day. A single afternoon level below 300 is a near-meaningless number, and it is the number a great many men are treated on. A confirmatory second morning draw is the difference between a diagnosis and a coincidence.

LH and FSH. These separate primary hypogonadism (the testes are failing) from secondary (the signal from above is failing). The distinction changes the treatment. Secondary hypogonadism in a younger man may be driven by something reversible — sleep apnoea, opioids, obesity, a pituitary lesion, over-training — and treating it with exogenous testosterone suppresses the axis further and shuts down fertility. That is a real cost paid by men who had a fixable problem.

Baseline haematocrit. Testosterone raises red cell mass. Erythrocytosis is the most common dose-limiting adverse effect and it is invisible without a CBC. Starting from an unknown baseline means you cannot tell a drift from a starting point.

PSA and prostate assessment. Narrower contraindications do not mean no assessment. It means the assessment informs a decision rather than reflexively blocking one.

Screening for what else explains the symptoms. Fatigue, low libido, poor concentration and weight gain are the presenting complaint for low testosterone and also for hypothyroidism, depression, iron deficiency, sleep apnoea and chronic under-recovery. Fifty-five percent of that cohort had sleep apnoea. Treating the testosterone and ignoring the apnoea gets you a man with a better lab value who still feels terrible — and a worse apnoea.

If you want the symptom side in more depth, we go through it in signs of low testosterone in men.

What a proper workup actually looks like

Concretely, in the order it should happen:

1. History and symptom review. Libido, morning erections, energy, mood, concentration, strength and body composition change, plus a deliberate hunt for confounders: sleep quality and snoring, alcohol, opioids and other medications, recent illness, training load, and weight trajectory.
2. Two morning total testosterone levels, drawn between roughly 5 and 10 a.m. on separate days, ideally fasting and not after a night of poor sleep or a hard training session.
3. SHBG and free or bioavailable testosterone where total is borderline. Sex hormone binding globulin shifts with age, insulin resistance, thyroid status and alcohol, and a normal total with a high SHBG can mask a genuinely low free level. We cover this trap in SHBG and sex hormone binding globulin.
4. LH and FSH, to classify primary versus secondary.
5. Prolactin where secondary hypogonadism is suggested, to screen for a pituitary cause.
6. CBC with haematocrit, as the baseline against which erythrocytosis is later judged.
7. PSA in men over 40 or with risk factors, plus prostate assessment as indicated.
8. Comprehensive metabolic panel, lipids, HbA1c or fasting insulin, ferritin, vitamin D and a full thyroid panel — the differential for “tired, flat, gaining weight” is wide, and the point of this step is to find the men who do not need testosterone at all.
9. Blood pressure, now explicitly relevant given the 2025 warning.
10. Fertility conversation, before anything is prescribed. Exogenous testosterone suppresses spermatogenesis. For a man who wants children in the next few years, that conversation changes the plan — often toward an agent that raises endogenous production instead.

Steps 2 and 4 are the two the ENDO 2026 review found missing most often, and they are the two that determine whether the diagnosis is real and what kind it is.

Formulation matters, and the trial evidence does not transfer evenly

TRAVERSE studied gel. Most men in the US are not on gel. That gap is worth being explicit about:

None of this makes injections unsafe. It means that when someone cites TRAVERSE to reassure you, the honest version includes “in men using gel,” and the monitoring you need — particularly haematocrit — is somewhat formulation-dependent.

A reasonable monitoring schedule

Interval varies with formulation and how you respond, but a defensible default:

Erythrocytosis is the effect most likely to require a dose change, and it is silent. Blood pressure is the effect most recently added to the label, and it is also silent. Both are cheap to measure and expensive to miss.

What this means for you, practically

If you are considering TRT. The label change is genuine good news: the therapy is better characterised than it was, and age-related decline is no longer an unstudied indication. But the 12% figure is the number to carry into a first appointment. Ask what the workup is before you ask what the protocol is. Two morning draws, LH and FSH, CBC, PSA where indicated, blood pressure, and a real look at sleep. A clinic that will write for you off one level and a questionnaire is a clinic that will manage you the same way.

If you are already on it. Nothing about the label change requires you to do anything, but it is a reasonable prompt to check two things. Was your original diagnosis established properly — and if not, is it worth confirming what your untreated baseline actually was? And is your blood pressure being monitored? That warning is newer than most men’s prescriptions.

If you have been avoiding it because of heart risk. TRAVERSE is the trial you were waiting for, and it enrolled exactly the higher-risk population you were worried about. It is also not a promise. Discuss it with someone who will tell you about the secondary signals as well as the primary result. Our page on TRT side effects covers what we watch and why.

If you are early in treatment. The first few months are where dose, formulation and haematocrit get sorted out. The first 30 days on TRT sets expectations for what should and should not be happening.

The standing picture, once the news decays

Regulatory language changes. The clinical structure underneath does not:

• Testosterone therapy is a long-term commitment to monitoring, not a prescription. The lab schedule is the treatment as much as the medication is.
• Diagnosis precedes treatment. Two morning levels, gonadotropins, and an honest look for other causes.
• Formulation matters. Gels, injections and pellets differ in peak levels, haematocrit effect and convenience, and the trial evidence is not evenly distributed across them.
• Symptoms are the endpoint, not the number. A total testosterone in the upper reference range on a man who still feels flat means something is being missed — often thyroid, sleep, SHBG, or iron.
• Blood pressure is now an explicit part of the picture. Measure it, and keep measuring it.

Where we sit

We read the 2026 label change as a correction of a genuine over-caution that pushed men toward unmonitored sources for two decades. We read the Endocrine Society statement and the 12% figure as an equally fair criticism of how the category is being practised — including by clinics that look a lot like ours from the outside.

The way to be on the right side of both is unglamorous: do the workup, document the diagnosis, monitor the things that can go wrong, and be willing to tell a man that his problem is his sleep rather than his testosterone.

If you want that version, our testosterone therapy page sets out how we run it, and a consult starts with the labs rather than the prescription.

---

This article is for general information and is not medical advice. It describes labeling and guideline developments current as of early August 2026. Testosterone therapy carries risks including erythrocytosis, effects on fertility, and increases in blood pressure. Do not start, stop or adjust hormone therapy without a qualified clinician who knows your history.

Sources

1. U.S. Department of Health and Human Services. “HHS Announces Requested Updates to Testosterone Therapy Product Labels.” 2026.
2. U.S. Food and Drug Administration. “FDA issues class-wide labeling changes for testosterone products.” fda.gov
3. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). New England Journal of Medicine, 2023. ClinicalTrials.gov NCT03518034.
4. Endocrine Society. Scientific statement on the diagnosis and management of hypogonadism, 16 July 2026.
5. Papaleontiou M, et al. “Testosterone therapy in men may be overprescribed, inconsistent with clinical guidelines.” Presented at ENDO 2026, Endocrine Society.